Full-Time

Facilities Manager

Superluminal Medicines

Superluminal Medicines

51-200 employees

ML-driven design of candidate small molecules

No salary listed

Boston, MA, USA

In Person

Primarily onsite, with participation in an on-call rotation and occasional extended hours for emergencies or facility issues.

Bachelor's

Category
Facilities Operations (1)
Required Skills
HVAC
OSHA
Plumbing

Get referred to Superluminal Medicines

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Facilities Management, Engineering, Biotechnology, or a related technical field is required.
  • Five to eight years of facilities management experience supporting a biotechnology, pharmaceutical, or laboratory environment is required.
  • Experience managing third-party contractors or service providers, including scopes of work, schedules, performance, documentation, and issue resolution.
  • Experience with building systems, including electrical, heating, ventilation, and air conditioning, and plumbing.
  • Experience leading regulatory requirements such as OSHA, HAZWOPER, and DOT.
  • Experience managing contractors, vendors, and service agreements.
  • Experience planning and executing projects, organizing workflows, solving operational problems, and communicating with cross-functional teams.
  • Experience managing competing priorities and shifting timelines within an R&D environment.
  • Ability to participate in the approved onsite and on-call schedule, with or without reasonable accommodation.
Responsibilities
  • Oversee the daily operation, maintenance, and functionality of laboratory, office, and support spaces to ensure a compliant, efficient, and fully operational work environment.
  • Develop and manage preventive maintenance programs for building systems and facility assets.
  • Oversee the maintenance and performance of critical building systems, including HVAC, electrical, plumbing, life safety, and other mechanical infrastructure.
  • Coordinate facility work orders, building services, preventive maintenance, inspections, and corrective actions while serving as the primary point of contact with property management and contractors.
  • Maintain maintenance records, preventive maintenance schedules, inspections, and compliance documentation.
  • Perform or coordinate general repairs and maintenance while minimizing disruption to research activities.
  • Lead facility improvement projects by managing schedules, execution, contractors, and budgets while minimizing operational downtime.
  • Manage the organization's shipping and receiving operations.
  • Oversee facility access and security programs by administering badges, parking passes, visitor access, and security protocols, and serve as the primary point of contact for security-related matters.
  • Partner with cross-functional teams to support laboratory operations, renovations, equipment installations, and space planning.
  • Coordinate laboratory infrastructure and utility services, including house gas systems, vacuum, deionized and reverse-osmosis water, and other building systems supporting research activities.
  • Ensure uninterrupted availability of critical laboratory utilities through preventive maintenance, vendor service, emergency response, and contingency plans.
  • Manage shipping and receiving operations supporting laboratory equipment, materials, and research activities.
  • Manage laboratory support utilities and services, including procurement, inventory, storage, and vendor management of dry ice, wet ice, compressed gases, cryogenic liquids, and other laboratory utilities.
  • Manage relationships with external vendors, contractors, and service providers.
  • Participate in vendor selection, contract negotiations, and performance management.
  • Monitor service-level agreements and vendor performance metrics.
  • Identify opportunities to improve operational efficiency, reduce costs, and optimize facility performance.
  • Participate in an on-call rotation.
  • Assess the operational impact of incidents, communicate with affected teams, escalate material risks, and document follow-up actions.
  • Support occasional extended hours for planned shutdowns, urgent repairs, inspections, or emergencies.
Desired Qualifications
  • Experience supporting biotechnology, pharmaceutical, life-science, or other research laboratories.
  • Experience managing facility renovations, laboratory buildouts, or capital improvement projects.
  • Experience with computerized maintenance management systems.
  • Experience working in a growing company with changing space, equipment, and operating needs.
Superluminal Medicines

Superluminal Medicines

View

Superluminal Medicines develops small-molecule drug discovery solutions by combining deep biology, chemistry, and machine learning. It creates candidate-ready compounds with high speed and accuracy, using a proprietary big data platform and predictive design models to model protein shapes and design selective compounds that induce precise structural changes for therapeutic effects. The company collaborates with pharmaceutical and biotech firms, licensing its technology and pursuing milestone-based payments, rather than selling products outright. This partnership-centric model helps clients accelerate their drug discovery programs in a highly competitive market. The company aims to shorten the path from target to clinical candidate by delivering well-characterized, selective small molecules efficiently.

Company Size

51-200

Company Stage

Series A

Total Funding

$153M

Headquarters

Boston, Massachusetts

Founded

2023

Get referred to Superluminal Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lilly's February 2026 update reaffirmed up to $1.3B in payments.
  • Superluminal expects an IND submission in late 2026 for obesity.
  • RA Capital, Insight, NVentures, Catalio, and Lilly funded the $120M Series A.

What critics are saying

  • Lilly gets exclusive rights, so Superluminal loses downstream economics.
  • The lead obesity asset still needs 2026 human data after IND filing.
  • A failed MC4R program would crush platform credibility and future partnering.

What makes Superluminal Medicines unique

  • Superluminal combines protein dynamics, structural biology, and ML on GPCRs.
  • Lilly backed the 2024 Series A and signed a 2025 $1.3B pact.
  • Its lead MC4R obesity program entered IND-enabling studies in July 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Tuition Reimbursement

Meal Benefits

Commuter Benefits

Pet Insurance

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

31%

1 year growth

31%

2 year growth

31%
The Pharma Letter
Aug 15th, 2025
Lilly and Superluminal work on GPCR drugs for cardiometabolic diseases

Eli Lilly (NYSE: LLY) has entered into a collaboration with Boston-based Superluminal Medicines to develop small-molecule therapies for undisclosed G protein-coupled receptor (GPCR) targets linked to cardiometabolic diseases and obesity.

Fierce Biotech
Aug 14th, 2025
Superluminal secures $1.3B pact with backer Lilly to develop cardiometabolic, obesity drugs

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech. | Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G protein-coupled receptor biotech.

BioWorld
Aug 14th, 2025
Superluminal, Lilly in $1.3B Deal

Superluminal Medicines Inc. has entered a collaboration with Eli Lilly and Co. in a deal worth up to $1.3 billion. The partnership aims to develop therapies for cardiometabolic diseases and obesity by targeting undisclosed G protein-coupled receptors. The deal includes up-front and near-term investments, an equity investment, development and commercial milestones, and tiered royalties on net sales.

BioWorld
Aug 14th, 2025
Superluminal joins a $1.3B deal with series A backer Lilly

Superluminal Medicines Inc. and Eli Lilly and Co. are collaborating in a deal to develop cardiometabolic disease and obesity therapies by aiming at undisclosed G protein-coupled receptor targets.

FinSMEs
Sep 9th, 2024
Superluminal Medicines Closes $120M Series A Funding

Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding